BACKGROUND There are many causes of chronic colitis and diarrhea, including the effects of chemotherapy. Mutations in the UGT1A1 gene can be associated with increased toxicity from irinotecan-based chemotherapy. This report is of a case of delayed diagnosis of Clostridium difficile (C. difficile) colitis in a 48-year-old woman with a homozygous mutation of the UGT1A1 gene treated with chemotherapy for colorectal carcinoma. CASE REPORT A 48-year-old woman with a low-differentiated colonic adenocarcinoma was treated after surgery with irinotecan, 5 fluorouracil, and panitumumab and had a history of chronic and severe diarrhea. Genetic testing identified a mutation in the UGT1A1 gene associated with increased toxicity to irinotecan, and the EIA tests performed for evaluation of C. difficile toxins A and B showed repeatedly negative results. Replacement of irinotecan with oxaliplatin did not have significant therapeutic results, but these were achieved by the administration of active antibiotics against C. difficile (metronidazole, vancomycin, and fidaxomicin). CONCLUSIONS This report has shown that in complex cases where patients are treated with chemotherapy and have increased susceptibility to drug toxicity, chronic diarrhea may still have an infectious cause. Only when the diagnosis is correctly made can the patient be appropriately treated.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895255 | PMC |
http://dx.doi.org/10.12659/AJCR.934361 | DOI Listing |
EBioMedicine
January 2025
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Heart and Vascular Institute, UPMC, Pittsburgh, PA, USA.
Background: Preclinical data have shown that low levels of metabolites with anti-inflammatory properties may impact metabolic disease processes. However, the association between mid-life levels of such metabolites and long-term ASCVD risk is not known.
Methods: We characterised the plasma metabolomic profile (1228 metabolites) of 1852 participants (58.
PeerJ
January 2025
Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background: Plasma membrane tension-related genes (MTRGs) are known to play a crucial role in tumor progression by influencing cell migration and adhesion. However, their specific mechanisms in bladder cancer (BLCA) remain unclear.
Methods: Transcriptomic, clinical and mutation data from BLCA patients were collected from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
Diagnostics (Basel)
December 2024
Department of Molecular Biology and Genetics, Biruni University, Merkezefendi, 75 Sk No:1-13 M.G., 34015 Istanbul, Turkey.
Background/aim: Loss of smell, also known as anosmia, is a prevalent and often prolonged symptom following infection with SARS-CoV-2. While many patients regain olfactory function within weeks, a significant portion experience persistent anosmia lasting over a year post-infection. The underlying mechanisms responsible for this sensory deficit remain largely uncharacterized.
View Article and Find Full Text PDFGenes (Basel)
December 2024
Department of Paediatrics Hemato-Oncology and Paediatric Gastroenterology, Pomeranian Medical University, 70-204 Szczecin, Poland.
Background: Hexokinase (HK) deficiency is a rare autosomal recessively inherited disease manifested by chronic nonspherocytic hemolytic anemia. Most patients present with a mild to severe course of the disease (fetal hydrocephalus, neonatal hyperbilirubinemia, severe anemia). We reviewed 37 cases of patients with hexokinase deficiency described so far, focusing on the severity of the disease, clinical presentation, treatment applied, and genetic test results.
View Article and Find Full Text PDFFront Cell Dev Biol
December 2024
Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Aim: This study aims to compare the efficiencies and toxicities of pegylated liposomal doxorubicin (PLD) based and epirubicin based chemotherapeutic regimens as neoadjuvant chemotherapy (NAC) for early breast cancer.
Patients And Methods: We retrospectively analyzed 391 patients with stage II-III breast cancer who received NAC in multiple centers. The efficiencies and toxicities of PLD and epirubicin based NAC regimens were compared by using both propensity-score matched (PSM) and unmatched data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!